CDKN2A deletion
Showing 1 - 25 of 971
Advanced Solid Tumor, CDKN2A, NSCLC Trial (Milademetan, Atezolizumab)
Withdrawn
- Advanced Solid Tumor
- +9 more
- (no location specified)
Oct 16, 2023
22Q11 Deletion Syndrome, tACS Trial (at-home tACS using Starstim-Home tES)
Not yet recruiting
- 22Q11 Deletion Syndrome
- tACS
- at-home tACS using Starstim-Home tES
- (no location specified)
Dec 15, 2022
HPV-unrelated Head and Neck Squamous Cell Carcinoma Trial in Saint Louis (Palbociclib, Cetuximab)
Recruiting
- HPV-unrelated Head and Neck Squamous Cell Carcinoma
-
Saint Louis, MissouriWashington University School of Medicine
Apr 7, 2022
Angelman Syndrome Trial (60 mg QD Alogabat, 40 mg QD Alogabat, 7 mg QD Alogabat)
Not yet recruiting
- Angelman Syndrome
- 60 mg QD Alogabat
- +4 more
- (no location specified)
Feb 1, 2023
GBM, Glioblastoma, Brain Tumor Trial in Dallas (Abemaciclib, Bevacizumab)
Active, not recruiting
- GBM
- +3 more
-
Dallas, TexasUT Southwestern Medical Center
Jan 23, 2022
People Who Have Genetic Changes and Features of Autism: Simons
Recruiting
- 16P11.2 Deletion Syndrome
- +184 more
-
New York, New York
- +1 more
Jan 6, 2023
22q11.2 Deletion Syndrome Trial in Philadelphia (NFC-1)
Completed
- 22q11.2 Deletion Syndrome
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Mar 24, 2022
Glioma (Diagnosis), Liquid Biopsy, Deep Learning Trial in Wuhan, Nanchang (Prediction of glioma grading and molecular subtype)
Recruiting
- Glioma (Diagnosis)
- +2 more
- Prediction of glioma grading and molecular subtype
-
Wuhan, Hubei, China
- +1 more
Sep 8, 2022
An Intervention to Increase Genetic Testing in Families Who May
Recruiting
- BRCA1 Mutation
- +21 more
- Intervention Arm At-risk Relative/ARR Contacts
- +5 more
-
Basking Ridge, New Jersey
- +7 more
Nov 22, 2022
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast
Not yet recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +2 more
- Binimetinib
- +5 more
- (no location specified)
Nov 8, 2022
CDKN2A-p16 Positive, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell
Recruiting
- CDKN2A-p16 Positive
- +5 more
- Alpelisib
- +3 more
-
Tucson, ArizonaThe University of Arizona Medical Center-University Campus
Mar 7, 2022
High Risk Prostate Cancer to Determine Prognosis
Active, not recruiting
- Prostate Cancer
-
Gatineau, Quebec, Canada
- +7 more
Sep 20, 2021
Chronic Lymphocytic Leukemia, 17p Deletion, Cancer of the Blood and Bone Marrow Trial in Worldwide (ABT-199 (Main Cohort),
Completed
- Chronic Lymphocytic Leukemia
- +2 more
- ABT-199 (Main Cohort)
- ABT-199 (Safety Expansion Cohort)
-
Tucson, Arizona
- +47 more
Nov 19, 2021
Germline Mutations Associated With Hereditary Pancreatic Cancer
Recruiting
- Pancreatic Cancer
- Pancreatic Adenocarcinoma
- Invitae Multi-Cancer Panel ®
-
Mexico City, MexicoInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubi
Mar 22, 2022
Neurofibromatosis 1 Trial run by the National Cancer Institute (NCI) (Abemaciclib)
Recruiting
- Neurofibromatosis 1
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Chronic Lymphocytic Leukemia Trial in Worldwide (Venetoclax)
Completed
- Chronic Lymphocytic Leukemia
-
Louisville, Kentucky
- +66 more
Nov 9, 2022
Examining Genetic Factors That Affect Severity of 22q11.2
Recruiting
- DiGeorge Syndrome
- 22q11.2 Deletion Syndrome
-
New York, New York
- +1 more
Jul 18, 2022
Photoaging Trial (In a double-blinded fashion, 250 mg CANNAXR cream, Topical VEHICLE cream)
Not yet recruiting
- Photoaging
- In a double-blinded fashion, 250 mg CANNAXR cream
- Topical VEHICLE cream
- (no location specified)
Aug 23, 2022
